3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
111
Carcinoma, Non-Small-Cell Lung
102
Prostatic Neoplasms
66
Multiple Myeloma
64
Neoplasm Metastasis
63
Colorectal Neoplasms
63
Neoplasms
59
Lung Neoplasms
52
Leukemia, Myeloid, Acute
41
Carcinoma, Hepatocellular
41
Recurrence
40
Lymphoma
40
Leukemia, Lymphocytic, Chronic, B-Cell
36
Pancreatic Neoplasms
34
Melanoma
34
Head and Neck Neoplasms
27
Glioblastoma
26
Rectal Neoplasms
25
Ovarian Neoplasms
25
Lymphoma, Large B-Cell, Diffuse
25
Leukemia
24
Brain Neoplasms
24
Squamous Cell Carcinoma of Head and Neck
23
Hematologic Neoplasms
23
Carcinoma, Renal Cell
23
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Myelodysplastic Syndromes
20
Colonic Neoplasms
20
Triple Negative Breast Neoplasms
19
Lymphoma, Non-Hodgkin
19
Interventions
ogalvibart
1
crexavibart
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Withdrawn
×
Purpura, Thrombocytopenic, Idiopathic
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn